Johnson & Johnson (JNJ) PEG Ratio: 0.21
Is Johnson & Johnson’s PEG ratio high or low?
Johnson & Johnson's PEG ratio of 0.21 is 25% below its 5-year average of 0.28, near the low end of its 5-year range (0.11–0.52).
The PEG ratio for Johnson & Johnson (JNJ) is 0.21. It is equal to its 12-month average by 0.00% (0.21).
JNJ PEG Ratio Chart
JNJ Average PEG Ratio Chart
JNJ Current vs Average PEG Ratio Chart
JNJ PEG Ratio Metrics
PEG RATIO
0.21
PEG RATIO AVG TTM
0.21
PEG RATIO AVG 3Y
0.16
PEG RATIO AVG 5Y
0.28
PEG RATIO AVG 10Y
0.58
PEG RATIO AVG 15Y
0.85
PEG RATIO AVG 20Y
0.87
CURRENT VS TTM AVG
+0.00%
CURRENT VS 3Y AVG
+31.25%
CURRENT VS 5Y AVG
-25.00%
CURRENT VS 10Y AVG
-64.04%
CURRENT VS 15Y AVG
-75.36%
CURRENT VS 20Y AVG
-75.98%
JNJ Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | — | 0.21 | 0.21 | 0.16 | 0.28 |
| Pfizer Inc. (PFE) | $146.36B | N/A | 0.07 | 0.13 | 0.16 |
| Merck & Co., Inc. (MRK) | $293.02B | 1.81 | 0.91 | 1.19 | 0.93 |
| AbbVie Inc. (ABBV) | $399.54B | N/A | 4.69 | 3.25 | 2.98 |
| Eli Lilly and Company (LLY) | $1.07T | 0.49 | 0.57 | 1.89 | 1.89 |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 1.67 | 0.24 | 0.24 | 0.18 |
Growth-Adjusted Valuation
PEG Ratio
0.21
P/E Ratio
27.6
Johnson & Johnson PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson PEG Ratio FAQ
- What is the PEG ratio for Johnson & Johnson (JNJ)?
- The PEG ratio for JNJ stock is 0.21.
- Is Johnson & Johnson's PEG ratio high or low?
- Johnson & Johnson's PEG ratio of 0.21 is 25% below its 5-year average of 0.28, near the low end of its 5-year range (0.11–0.52).
- What is the TTM average PEG ratio for Johnson & Johnson (JNJ)?
- The TTM average PEG ratio for JNJ stock is 0.21.
- What is the 3Y average PEG ratio for Johnson & Johnson (JNJ)?
- The 3Y average PEG ratio for JNJ stock is 0.16.
- What is the 5Y average PEG ratio for Johnson & Johnson (JNJ)?
- The 5Y average PEG ratio for JNJ stock is 0.28.
- What is the 10Y average PEG ratio for Johnson & Johnson (JNJ)?
- The 10Y average PEG ratio for JNJ stock is 0.58.
- What is the 15Y average PEG ratio for Johnson & Johnson (JNJ)?
- The 15Y average PEG ratio for JNJ stock is 0.85.
- What is the 20Y average PEG ratio for Johnson & Johnson (JNJ)?
- The 20Y average PEG ratio for JNJ stock is 0.87.
Johnson & Johnson PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2025-12-28 | 0.21 |
| 2023-12-31 | 0.11 |
| 2022-01-02 | 0.52 |
| 2018-12-31 | 0.02 |
| 2016-12-31 | 2.06 |
| 2014-12-31 | 0.91 |
| 2013-12-31 | 0.74 |
| 2012-12-31 | 1.72 |
| 2010-12-31 | 1.38 |
| 2008-12-31 | 0.48 |
| 2006-12-31 | 1.56 |
| 2005-12-31 | 0.78 |
| 2004-12-31 | 1.69 |
| 2003-12-31 | 2.13 |
| 2002-12-31 | 1.38 |
| 2001-12-31 | 2.37 |
| 2000-12-31 | 2.06 |
| 1999-12-31 | 1.01 |
| 1997-12-31 | 1.94 |
| 1996-12-31 | 1.33 |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato